Research view
Switch to patient viewGastric and oesophageal cancer: trials that stopped early
Trials on gastric and oesophageal cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
131 stopped trials give a reason in the registry, latest registry update first. 5 more give no reason and are not listed.
Terminated
Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer
Reason given in the registry “R\&d strategy adjustment”
Quoted unchanged from ClinicalTrials.gov; record updated 20 Aug 2025.
- Ended
- Apr 2024
- Phase
- Phase 2/3
- Run by
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Registry record
- NCT05149807
Withdrawn
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
Reason given in the registry “Corporate business decision”
Quoted unchanged from ClinicalTrials.gov; record updated 30 Jul 2025.
- Phase
- Phase 1/2
- Run by
- Artiva Biotherapeutics, Inc.
- Registry record
- NCT05678205
Terminated
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
Reason given in the registry “Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic component in the study design.”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Jul 2025.
- Ended
- May 2025
- Phase
- Phase 2
- Run by
- Telix Pharmaceuticals (Innovations) Pty Ltd
- Registry record
- NCT05563272
Terminated
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Reason given in the registry “Business decision”
Quoted unchanged from ClinicalTrials.gov; record updated 25 Jun 2025.
- Ended
- Oct 2024
- Phase
- Phase 1
- Run by
- POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
- Registry record
- NCT05432193
Terminated
Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
Reason given in the registry “Due to modification of company strategy.”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Jun 2025.
- Ended
- Feb 2024
- Phase
- Phase 2
- Run by
- BeiGene
- Registry record
- NCT05461794
Terminated
TAC T-cells for the Treatment of HER2-positive Solid Tumors
Reason given in the registry “Study terminated by Sponsor for commercial reasons”
Quoted unchanged from ClinicalTrials.gov; record updated 8 Jun 2025.
- Ended
- Mar 2024
- Phase
- Phase 1/2
- Run by
- Triumvira Immunologics, Inc.
- Registry record
- NCT04727151
Withdrawn
Defining Musical Toxicity and Its Effect on Patient Well-being
Reason given in the registry “Resident working with study left institution”
Quoted unchanged from ClinicalTrials.gov; record updated 4 Jun 2025.
- Ended
- May 2025
- Run by
- Mayo Clinic
- Registry record
- NCT06494046
Terminated
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Reason given in the registry “Study termination was based on strategic considerations and not due to specific safety reasons or a request from a regulatory authority.”
Quoted unchanged from ClinicalTrials.gov; record updated 28 May 2025.
- Ended
- Dec 2024
- Phase
- Phase 1
- Run by
- Pfizer
- Registry record
- NCT04152018
Terminated
Transnasal Esophagoscopy (TNE) Esophageal Cancer Screening
Reason given in the registry “Transnasal Esophagoscopy (TNE) scope is no longer manufactured so the study is unable to be continued.”
Quoted unchanged from ClinicalTrials.gov; record updated 25 May 2025.
- Ended
- Mar 2025
- Run by
- University of Illinois Chicago
- Registry record
- NCT05480891
Terminated
A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)
Reason given in the registry “Study was discontinued because of slow enrollment and organizational priorities and not because of any findings related to safety or efficacy.”
Quoted unchanged from ClinicalTrials.gov; record updated 11 May 2025.
- Ended
- Apr 2024
- Phase
- Phase 2
- Run by
- Imugene Limited
- Registry record
- NCT05311176
Terminated
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Reason given in the registry “Study terminated by sponsor”
Quoted unchanged from ClinicalTrials.gov; record updated 8 May 2025.
- Ended
- Aug 2024
- Phase
- Phase 1/2
- Run by
- Hutchmed
- Registry record
- NCT04579757
Terminated
Early IntraVenous Administration of Nutritional Support
Reason given in the registry “Changes in anticancer treatment protocols which limit recruitment”
Quoted unchanged from ClinicalTrials.gov; record updated 7 May 2025.
- Ended
- Jul 2024
- Run by
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Registry record
- NCT03949907
Suspended
Acetic Acid for the Detection of Esophageal Neoplasms
Reason given in the registry “not enough patients enrolled”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Apr 2025.
- Ended
- May 2025
- Run by
- Coordinación de Investigación en Salud, Mexico
- Registry record
- NCT04054713
Withdrawn
Study of OB-002 in Patients With Refractory Metastatic Cancer
Reason given in the registry “study terminated due to changes in the drug development plan”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Apr 2025.
- Ended
- Aug 2025
- Phase
- Phase 1
- Run by
- Orion Biotechnology Polska Sp. z o.o.
- Registry record
- NCT05940844
Terminated
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Reason given in the registry “Business decision”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Apr 2025.
- Ended
- Feb 2024
- Phase
- Phase 2
- Run by
- Elevation Oncology
- Registry record
- NCT04383210
Terminated
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Reason given in the registry “Early discontinuation based on strategic sponsor decision not driven by any safety concerns.”
Quoted unchanged from ClinicalTrials.gov; record updated 2 Apr 2025.
- Ended
- Oct 2024
- Phase
- Phase 1/2
- Run by
- Kymab Limited
- Registry record
- NCT03829501
Terminated
Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC
Reason given in the registry “Sponsor Decision”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Mar 2025.
- Ended
- Jan 2025
- Phase
- Phase 1
- Run by
- Viracta Therapeutics, Inc.
- Registry record
- NCT05166577
Terminated
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Reason given in the registry “Study closed due to portfolio prioritization”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Mar 2025.
- Ended
- Nov 2023
- Phase
- Phase 2
- Run by
- Seagen Inc.
- Registry record
- NCT04032704
Terminated
Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma
Reason given in the registry “Several clinical trials had showed that anti-PD-1 agents combined with chemotherapy as neoadjuvant treatment could increase pCR rate in 2024. In order to protect the interest of patients, this trial was stopted.”
Quoted unchanged from ClinicalTrials.gov; record updated 21 Feb 2025.
- Ended
- Nov 2024
- Phase
- Phase 2
- Run by
- Peking University
- Registry record
- NCT04804696
Terminated
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients
Reason given in the registry “slow accrual”
Quoted unchanged from ClinicalTrials.gov; record updated 20 Feb 2025.
- Ended
- Oct 2024
- Phase
- Early phase 1
- Run by
- Mayo Clinic
- Registry record
- NCT04213794
Suspended
AN0025 and Chemoradiotherapy Combination in Esophageal Cancer
Reason given in the registry “The study is not stopped but the enrollment is suspended until a further decision from sponsor.”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Feb 2025.
- Ended
- Dec 2025
- Phase
- Phase 1
- Run by
- Adlai Nortye Biopharma Co., Ltd.
- Registry record
- NCT05191667
Terminated
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Reason given in the registry “Study closed due to portfolio prioritization”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Feb 2025.
- Ended
- Dec 2023
- Phase
- Phase 1
- Run by
- Seagen Inc.
- Registry record
- NCT04254107
Terminated
A Study of SGN-ALPV in Advanced Solid Tumors
Reason given in the registry “Study closed due to portfolio prioritization”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Feb 2025.
- Ended
- Dec 2023
- Phase
- Phase 1
- Run by
- Seagen Inc.
- Registry record
- NCT05229900
Terminated
A Study of SGN-STNV in Advanced Solid Tumors
Reason given in the registry “Study closed due to portfolio prioritization”
Quoted unchanged from ClinicalTrials.gov; record updated 7 Feb 2025.
- Ended
- Mar 2024
- Phase
- Phase 1
- Run by
- Seagen Inc.
- Registry record
- NCT04665921
Withdrawn
Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers
Reason given in the registry “PI Decision”
Quoted unchanged from ClinicalTrials.gov; record updated 7 Feb 2025.
- Ended
- Dec 2025
- Phase
- Phase 1
- Run by
- Ohio State University Comprehensive Cancer Center
- Registry record
- NCT05296005
Withdrawn
Molecular Analysis of Gastric and OEsophageal Cancers STudy
Reason given in the registry “Never opened to recruitment due to lack of funding”
Quoted unchanged from ClinicalTrials.gov; record updated 6 Feb 2025.
- Run by
- Royal Marsden NHS Foundation Trust
- Registry record
- NCT06702384
Withdrawn
Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201
Reason given in the registry “Determined that enrollment would be limited due to the change in care setting.”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Jan 2025.
- Phase
- Phase 1
- Run by
- GC Cell Corporation
- Registry record
- NCT06341647
Terminated
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
Reason given in the registry “Study was terminated due to strategic considerations and not due to safety.”
Quoted unchanged from ClinicalTrials.gov; record updated 16 Jan 2025.
- Ended
- Nov 2023
- Phase
- Phase 1
- Run by
- Pfizer
- Registry record
- NCT04171141
Terminated
Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer
Reason given in the registry “Poor accrual and funding sponsor declared bankruptcy.”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Jan 2025.
- Ended
- Nov 2024
- Phase
- Phase 2
- Run by
- Washington University School of Medicine
- Registry record
- NCT04162665
Terminated
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Reason given in the registry “Required re-formulation of DFMO from IV to capsule to maintain safety”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Dec 2024.
- Ended
- Dec 2024
- Phase
- Phase 1/2
- Run by
- Aminex Therapeutics, Inc.
- Registry record
- NCT05500508
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.